Biotech ' s Drug Pipeline Expands From Melanoma To Other Cancers

is the IBD Stock of the Day as the biotech expands its drug pipeline. IMCR stock has forged a cup with handle with an entry point of 65.10. X On the stock market today, the biotechnology company rose 4.8% to 64.67. The company's primary product, Kimmtrak, is a treatment for a form of melanoma. In…#ibdstockofday #kimmtrak #immunocore #otherimmunocoredrugs #imcr #jpmorgan #jessicafye #biotechstockapioneer #tcr #justinzelin
Source: Reuters: Health - Category: Consumer Health News Source Type: news